

Supplemental Table 1. Patient characteristics by race/ethnicity in patients with type 2 diabetes or at risk of diabetes

	Type 2 Diabetes * (n=4,662)			At-Risk of Type 2 Diabetes ** (n=10,222)		
	White, Non-Hispanic (n=2573)	Black, Non-Hispanic (n=1425)	Hispanic (n=664)	White, Non-Hispanic (n=6865)	Black, Non-Hispanic (n=2265)	Hispanic (n=1092)
Age, year	65.4 (13.9)	48.8 (12.9)	59.7 (13.9)	54.9 (17.7)	48.8 (15.5)	46.5 (15.5)
Age group, %						
<65	46.6	68.8	64.0	70.7	84.8	86.5
>=65	53.4	31.2	36.0	29.4	15.2	13.5
Sex, %						
Men	50.8	38.0	47.1	41.6	29.8	31.1
Women	49.2	62.0	52.9	58.4	70.2	68.9
Smoking, %						
Current	5.6	5.5	1.5	6.2	5.4	3.5
Former	27.2	13.5	6.5	20.4	12.2	7.1
Never	38.0	26.7	21.4	42.1	39.0	38.5
Unknown	29.2	54.3	70.6	31.4	43.4	50.9
Location						
Urban	90.0	99.4	99.4	93.5	99.7	99.7
Rural	3.5	0.1	0.2	3.9	0.0	0.1
Unknown	6.5	0.5	0.4	2.7	0.3	0.2
Comorbidity, %						
MI	13.8	11.3	13.4	3.7	2.3	2.8
Congestive heart failure	25.9	24.8	21.5	8.2	7.4	4.9
Peripheral vascular disease	21.5	17.2	17.6	7.7	4.4	4.2
Cerebrovascular disease	19.5	15.9	16.7	8.5	5.9	5.0
Chronic pulmonary disease	33.0	34.5	38.7	23.7	27.6	24.3
Liver disease, mild	15.4	13.1	18.5	7.5	6.8	9.3
Renal disease, mild to moderate	32.8	25.5	25.3	9.0	7.8	4.3
Any malignancy	12.6	9.3	7.8	10.0	7.1	5.3
Renal disease, severe	5.8	11.4	9.5	0.9	2.6	1.2
CCI Score	5.8 (3.1)	5.0 (3.1)	5.1 (3.2)	2.4 (2.5)	2.2 (1.7)	1.9 (1.4)

	Type 2 Diabetes * (n=4,662)			At-Risk of Type 2 Diabetes ** (n=10,222)		
	White, Non-Hispanic (n=2573)	Black, Non-Hispanic (n=1425)	Hispanic (n=664)	White, Non-Hispanic (n=6865)	Black, Non-Hispanic (n=2265)	Hispanic (n=1092)
Body Mass Index, kg/m ²	34.5 (7.9)	34.8 (8.8)	33.3 (7.5)	32.0 (7.0)	33.9 (7.8)	32.0 (6.5)
BMI category, %						
<18.5	0.4	0.6	0.2	0.2	0.2	0.1
18.5 to <25	7.4	9.3	9.6	9.1	6.6	7.9
25-29.9	21.4	20.9	24.0	34.9	26.8	33.3
30-39.9	47.6	43.9	46.5	41.4	44.4	45.2
40+	21.7	24.0	16.4	12.0	19.4	10.8
Unknown	1.5	1.3	3.3	2.4	2.6	2.7
SBP, mmHg ¹	130.8 (17.1)	135.2 (18.6)	132.9 (19.7)	126.6 (15.9)	129.3 (17.3)	123.7 (16.0)
DBP, mmHg ²	74.5 (10.9)	78.7 (11.2)	77.0 (11.3)	76.4 (10.3)	78.9 (11.0)	75.5 (10.4)
HDL chol, mg/dL ³	44.4 (12.6)	50.0 (16.1)	44.6 (13.7)	52.5 (15.1)	55.5 (16.5)	49
LDL chol, mg/dL ⁴	132.0 (47.0)	139.1 (46.7)	145.6 (49.9)	151.2 (41.4)	143.8 (41.5)	153.7 (41.7)
Time of COVID diagnosis, %						
March-June, 2020	19.1	40.8	41.6	18.1	36.3	41.8
July-Oct, 2020	25.0	25.0	22.4	26.3	29.4	23.4
Nov-Jan, 2021	55.9	34.2	36.0	55.6	34.3	34.8
HbA1c categories, %						
< 6.0%	11.4	12.0	6.9			
6.0-6.9%	25.3	21.5	21.5			
7.0-7.9%	18.0	13.8	16.4			
8.0-8.9%	8.6	9.1	8.3			
≥ 9.0%	11.5	15.9	17.5			
Missing	25.1	27.7	29.4			
HbA1c, mean (SD), % ⁵	7.4 (1.7)	7.8 (2.2)	7.9 (2.0)			
Any sulfonylureas, %	18.4	15.7	14.5			
Any metformin, %	37.0	48.1	44.7			
Any Insulin, %	34.0	41.1	46.2			
Any DPP-4 inhibitor,%	10.5	10.9	11.0			
Any GLP-1 agonist, %	4.5	5.0	3.8			
Any SGLT2 inhibitor, %	9.8	8.6	11.0			

Abbreviations: CCI: Charlson Comorbidity Index; BMI: Body Mass Index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: High-Density Lipoprotein; LDL: Low-Density Lipoprotein; HbA1c: Hemoglobin A1c; DPP-4 inhibitor: Dipeptidyl peptidase-4 inhibitor; GLP-1 agonist: Glucagon-like peptide-1 receptor agonist; SGLT-2: Sodium-glucose transport protein 2 (SGLT2) inhibitors

Data presented as mean (standard deviation) or percent

¹SBP n=14,627; ²DBP n=14,626; ³HDL n=7,880, ⁴LDL n=7,872, ⁵HbA1c n=3,427

* All p values <0.05 except congestive

Supplemental Table 2. Adjusted odds ratios (95% confidence intervals) for hospitalization only and severe outcomes in patients with type 2 diabetes or at risk of type 2 diabetes: Subgroup analysis

Factors	Type 2 Diabetes		At-Risk of Diabetes#	
	Hospitalization only	ICU/Intubation /Death	Hospitalization only	ICU/Intubation /Death
Total				
Black vs. White	1.08 (0.89, 1.32)	0.68 (0.52, 0.89)	1.54 (1.31, 1.80)	0.52 (0.38, 0.73)
Hispanic vs. white	1.73 (1.36, 2.19)	1.10 (0.78, 1.55)	1.77 (1.43, 2.18)	0.70 (0.45, 1.09)
Age <65				
Black vs. White	1.01 (0.77, 1.32)	0.61 (0.41, 0.91)	1.55 (1.29, 1.87)	0.74 (0.48, 1.15)
Hispanic vs. white	1.60 (1.16, 2.20)	1.14 (0.70, 1.86)	1.66 (1.30, 2.11)	1.15 (0.68, 1.94)
Age >=65				
Black vs. White	1.25 (0.93, 1.69)	0.82 (0.56, 1.20)	1.50 (1.10, 2.04)	0.90 (0.56, 1.43)
Hispanic vs. White	2.08 (1.43, 3.01)	1.13 (0.68, 1.87)	2.49 (1.58, 3.91)	1.59 (0.76, 3.29)
Men				
Black vs. White	1.23 (0.92, 1.64)	0.78 (0.52, 1.18)	1.53 (1.17, 2.00)	1.00 (0.63, 1.56)
Hispanic vs. White	1.58 (1.11, 2.24)	1.48 (0.92, 2.40)	1.72 (1.21, 2.46)	1.58 (0.89, 2.82)
Women				
Black vs. White	1.01 (0.78, 1.32)	0.58 (0.41, 0.84)	1.50 (1.23, 1.83)	0.66 (0.42, 1.04)
Hispanic vs. White	1.93 (1.39, 2.68)	0.78 (0.47, 1.30)	1.76 (1.36, 2.29)	0.94 (0.51, 1.74)
Mar-Jun 2020				
Black vs. White	1.55 (1.09, 2.19)	0.64 (0.43, 0.96)	1.41 (1.08, 1.84)	0.55 (0.33, 0.92)
Hispanic vs. White	2.43 (1.63, 3.65)	0.78 (0.46, 1.33)	1.47 (1.05, 2.04)	1.10 (0.62, 1.98)
July-Oct 2020				
Black vs. White	1.33 (0.91, 1.93)	0.73 (0.39, 1.36)	1.86 (1.41, 2.46)	1.38 (0.71, 2.68)
Hispanic vs. White	2.16 (1.32, 3.53)	2.85 (1.38, 5.88)	3.30 (2.29, 4.75)	2.07 (0.77, 5.57)
Nov 2020-Feb 2021				
Black vs. White	0.70 (0.49, 0.99)	0.70 (0.44, 1.10)	1.46 (1.09, 1.95)	0.90 (0.54, 1.50)
Hispanic vs. White	1.33 (0.86, 2.04)	1.12 (0.61, 2.05)	1.14 (0.72, 1.79)	0.92 (0.41, 2.07)

ICU: Intensive Care Unit

#At risk defined based on elevated BMI, prediabetes diagnosis, or elevated HbA1c.

Adjusted for age, sex, smoking status, CCI score, time of COVID diagnosis, BMI category, SBP (quartile), DBP (quartile), HDL level (quartile), LDL level (quartile). Additional adjustments for HbA1c level, insulin use, metformin use, DPP-4 inhibitor use, GLP-1R agonist use, and SGLT2 inhibitor use in the analyses of type 2 diabetes patients.